Matteucci, E
A provider will assess your goals, labs, and health history to tailor a plan that prioritizes both safety and results
The collaborations between biotech firms, academic institutions, and healthcare providers, as exemplified by Canadas diabetes framework development, are accelerating innovation and patient access, reinforcing North Americas position as the leader in the glucagon like peptide 1 analogs market
Among the 58% of adults who say they want to lose weight, nearly one-third (32%) expect to start a prescription GLP-1 drug in 2026, which translates to an estimated 48 million American adults including 9% who say they definitely will and 23% who say they probably will
The chart below shows the key differences between GLP-1 weight loss medications, Phentermine, Cell-Press, and I AM WonderFULL